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S U M M A R Y
Background: Cryptococcosis is a severe fungal infection with a high mortality rate among solid-organ
transplant recipients. Today, China is among the countries performing the most kidney transplants
worldwide, however data on the association of cryptococcosis with kidney transplantation in mainland
China remain scarce and fragmented.
Methods: We retrospectively analyzed cases of culture-conﬁrmed cryptococcosis following kidney
transplantation that have occurred at our hospital and reviewed the published cases in China over the
last 30 years.
Results: Cryptococcosis in kidney transplant recipients was mainly caused by Cryptococcus neoformans
var. grubii VNI strains and occurred most frequently in patients aged 41–50 years (37.9%, 11/29). The
average time to infection after kidney transplantation was 5.16  3.97 years. The clinical manifestations
were found to be diverse, with slight to moderate headache and fever, meningeal irritation, and high
cerebrospinal ﬂuid pressure being relatively common. Physicians should be alert to these symptoms among
kidney transplant recipients.
Conclusions: Cryptococcosis is a serious infection among kidney transplant recipients in mainland China.
It has unique characteristics, such as a relatively long time to onset after kidney transplantation, and
diverse clinical manifestations. Treatment with intrathecal injection of amphotericin B is considered
effective for central nervous system involvement. The ﬁndings of this study also highlight the urgent
need for multicenter, prospective, and multidisciplinary clinical studies and education on cryptococcosis
in kidney transplant recipients in China.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Cryptococcosis is the third most commonly occurring invasive
fungal infection among solid organ transplant (SOT) recipients.1–4
The Cryptococcus neoformans/Cryptococcus gattii species complex is
the major causative agent of this infection and has been divided
into two sibling species, i.e., C. neoformans (serotypes A, D, and AD)* Corresponding author. Tel.: +86 2181885494; fax: +86 2163520020.
** Corresponding author. Tel: +86 2181885493; fax: +86 2181885493.
E-mail addresses: panweihua@medmail.com.cn (W.-h. Pan),
liaowanqing@sohu.com (W.-q. Liao).
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http://dx.doi.org/10.1016/j.ijid.2014.05.028
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).and C. gattii (serotypes B and C).5,6 C. neoformans, including C.
neoformans var. grubii (serotype A)7 and C. neoformans var.
neoformans (serotypes D and AD), are globally distributed and
the dominant causes of cryptococcal infection,8,9 while C. gattii
more frequently causes cryptococcomas, and is more widely
distributed than previously thought.8–12
Several molecular methods, such as PCR ﬁngerprinting, have
been used to divide the C. neoformans/C. gattii species complex
into the following eight major genotypes: VNI (serotype A), VNII
(serotype A), VNIII (serotype AD), and VNIV (serotype D) of C.
neoformans; and VGI, VGII, VGIII, and VGIV of C. gattii.13,14
Previous molecular epidemiology studies on cryptococcosis have
revealed VNI to be the most represented genotype (70.5–89.6%)ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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other countries, kidney transplantation is the most common SOT
surgery carried out in China.19 Currently, the 5-year survival rate
of kidney transplant recipients in China has reached approxi-
mately 87.5% due to improvements in transplantation and other
techniques.19 However, cryptococcosis remains the main cause
of death in kidney transplant recipients.1–4 Although the
incidence of cryptococcosis in kidney transplant recipients
ranges from 0.2% to 5%,1,2 the mortality rate is 20% to 49%.1,20
Moreover, the clinical outcome of cryptococcosis is associated
with the genetic background of the isolate, the diagnosis, and the
treatment strategy.21–25
Cryptococcosis is a serious fungal disease causing an
estimated 140 000 new infections in Asia annually.26 However,
current understanding of cryptococcosis after kidney transplan-
tation is difﬁcult to determine, as comprehensive, detailed, and
accurate data are lacking worldwide, and this is particularly true
in China, which is among the countries performing the most
kidney transplantations.19 Data on kidney recipients with
cryptococcosis have been reported in numerous, separate case
studies, and most of these are written in Chinese.27–40
Consequently, information on the association of cryptococcosis
with kidney transplantation in China remains scarce and
fragmented. To ﬁll the gap in our knowledge, we sought to
retrospectively analyze cases of cryptococcosis that occurred
after kidney transplantation in our hospital and to review the
published reports in China, with a focus on the following four
topics: epidemiological characteristics, clinical manifestations,
diagnosis, and treatment proﬁle.
2. Materials and methods
2.1. Study design and setting
This study was conducted in a 1280-bed tertiary care mycosis
and organ transplant center in China. First, we retrospectively
reviewed the culture-conﬁrmed cryptococcosis cases associated
with kidney transplantation that occurred in Shanghai Changz-
heng Hospital over the previous 11 years, and analyzed the
genotype and antifungal susceptibilities of the clinical isolates.
Secondly, we conducted a comprehensive review of the reported
cases of cryptococcosis occurring in China from January 1982 to
December 2013.
2.2. DNA extraction
Genomic DNA was extracted as described previously.16 The
concentrations and qualities of the puriﬁed DNA were evaluated
with ﬂuorescence spectrophotometry (Colibri Microvolume Spec-
trometer, Berthold Titertek Instruments, Inc., Germany).
2.3. Genotype of the clinical isolates
We used two separate molecular techniques to identify the
genotype of each clinical isolate: PCR ﬁngerprinting and sequence
analysis of the internal transcribed spacer (ITS). First, the ITS region
was ampliﬁed with ITS5 and ITS4 primers using EasyPfu PCR
SuperMix (Transgen, Beijing, China) in total volumes of 25 ml with
20 ng of template DNA.14 PCR products were directly sequenced on
an ABI 3770 DNA sequencer twice in opposite directions to obtain a
reliable sequence. The genotype of these isolates was determined
by comparative analysis with the sequence of cryptococcal type
strains using software MEGA 6.06.15 Secondly, the PCR ﬁnger-
printing pattern based on single primer M13 was applied, as
described previously,12 and each clinical isolate of ﬁngerprinting
pattern was deﬁned manually by comparison to cryptococcal typestrains (CBS10085 (VNI), CBS10083 (VNII), CBS10080 (VNIII),
CBS10079 (VNIV)).
2.4. In vitro antifungal susceptibility testing
Broth microdilution testing was performed in accordance with
Clinical and Laboratory Standards Institute (CLSI) document M27-
A3.41 Standard antifungal powders of amphotericin B (AmB), 5-
ﬂuorocytosine (5-FC), ﬂuconazole (FCZ), itraconazole (ITZ), and
voriconazole (VCZ) were purchased from Sigma, Inc., Germany. The
ﬁnal concentrations of the antifungal agents were 0.016 to 8 mg/ml
for AmB, ITZ, and VCZ, and 0.125 to 64 mg/ml for 5-FC and FCZ. The
minimum inhibitory concentration (MIC) was deﬁned as the
lowest concentration of the drug that prevented growth (for AmB)
or produced a prominent reduction in growth (50%) compared to
the drug-free growth control (for the other antifungal agents). All
results were read visually after 72 h of incubation at 35 8C. Candida
parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were used
as quality control.
2.5. Clinical data analysis
We retrospectively reviewed the cases of culture-conﬁrmed
cryptococcosis in patients who had received a kidney transplan-
tation in our hospital. Next, we conducted a comprehensive
review using the following combinations of keywords cryptococ-
cosis and kidney transplantation; cryptococcosis and kidney
transplant; cryptococcosis and renal transplantation; cryptococ-
cosis and renal transplant; cryptococcal infection and kidney
transplantation; cryptococcal infection and kidney transplant;
cryptococcal infection and renal transplantation; cryptococcal
infection and renal transplant; Cryptococcus and renal transplan-
tation; Cryptococcus and renal transplant; Cryptococcus and
kidney transplantation; Cryptococcus and kidney transplant;
Cryptococcus and renal transplantation; Cryptococcus and renal
transplant. Using these keywords, we searched the entire CBM
disk database (China Biology and Medicine data disc, Institute of
Medical Information, Chinese Academy of Medical Science). The
search terms were also used to search the Chinese Medline
database for articles within the same period. Additional articles
were identiﬁed from the reference sections of the articles
retrieved.
3. Results
3.1. Genotype of the clinical isolates
A total of nine strains were isolated from nine cryptococcosis
patients who had received a kidney transplant in our hospital. All
of these isolates were identiﬁed as ITS type 1 in agreement with
comparable sequence analysis with the reference sequence
(GenBank AJ493551 (ITS type 1)). Similarly, these nine isolates
were grouped into genotype VNI by analysis of DNA bands of
ﬁngerprinting pattern (Supplementary Material Figure S1).
Hence, the most representative genotype of the cryptococcal
isolates from our kidney transplant patients was VNI/ITS type 1.
Details are given in Table 1.
3.2. In vitro antifungal susceptibility of the clinical isolates
The in vitro antifungal sensitivity ranges were as follows: 0.5–
1 mg/ml for AmB (mean  SD, 0.61  0.22 mg/ml), 1–8 mg/ml for
FCZ (3.3  2.2 mg/ml), 0.03–0.125 mg/ml for ITZ (0.093  0.039 mg/
ml), 0.03–0.125 mg/ml for VCZ (0.072  0.042 mg/ml), and 2–8 mg/ml
for 5-FC (5.1  2.3 mg/ml). Details are given in Table 1.
Table 1
In vitro antifungal sensitivity and genotype of the cryptococcal isolates from kidney transplant recipients in a Chinese university hospital, 2003–2013
Case Isolate Collection date Source Genotype GenBank
accession
number
In vitro antifungal sensitivity Ref.
AmB ITZ VCZ 5-FC FCZ
1 SCZT1 Nov 2003 CSF VNI KJ371108 0.5 0.06 0.06 8 4 This study
2 SCZT2 Dec 2005 CSF VNI KJ371109 0.5 0.125 0.06 4 8 This study
3 SCZT3 Apr 2008 CSF VNI KJ371110 1 0.125 0.125 4 4 This study
4 WH028 Oct 2008 CSF VNI KJ371111 0.5 0.125 0.125 4 4 17
5 SCZT4 Sept 2009 Sputum VNI KJ371112 0.5 0.03 0.03 8 2 This study
6 SCZT5 Aug 2010 CSF VNI KJ371113 0.5 0.06 0.06 2 1 This study
7 SCZT6 Nov 2011 CSF VNI KJ371114 0.5 0.06 0.03 4 1 This study
8 SCZT7 Apr 2012 Sputum VNI KJ371115 0.5 0.125 0.03 8 2 This study
9 SCZT8 July 2012 CSF VNI KJ371116 1 0.125 0.125 4 4 This study
Mean  SD 0.61  0.22 0.093  0.039 0.072  0.042 5.1  2.3 3.3  2.2
AmB, amphotericin B; ITZ, itraconazole; VCZ, voriconazole; 5-FC, 5-ﬂuorocytosine; FCZ, ﬂuconazole; CSF, cerebrospinal ﬂuid; SD, standard deviation.
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In addition to the nine cases identiﬁed in our hospital, a total of
20 cases of cryptococcosis following kidney transplantation were
reported in 13 published articles (one in English and 12 in Chinese)
between January 1982 and February 2012. These cases were
collected from 10 economically and technologically developed
cities in China, including Shanghai (n = 9), Nanjing (n = 7), Beijing (n
= 3), Fuzhou (n = 3), Chengdu (n = 2), Changchun (n = 1), Lishui (n =
1), Tangshan (n = 1), Hefei (n = 1), and Guangzhou (n = 1). Two
recipients had been exposed to pigeon droppings a year before the
cryptococcal infection. In this survey, 18 of the patients were male
and 11 female. The mean age at onset was 40.6  10.4 years and the
most heavily represented age group was 41–50 years (37.9%, 11/29).
The most common site of infection was the brain (93.1%, 27/29).
Based on an analysis of the 14 cases with a clear description of
underlying disease (Table 2), the most common underlying disease
was hepatitis C (21.4%, 3/14) and the second most common was type
2 diabetes mellitus (14.3%, 2/14). Other underlying diseases were
hepatitis B (7.1%, 1/14), tuberculosis (7.1%, 1/14), and hypertension
(7.1%, 1/14). None of the recipients was found to be HIV-positive in
this study. Details are shown in Table 2.
3.4. Clinical manifestations
In this study, the average time to onset was found to be 5.16 
3.97 years, and the mortality rate was 34.5% (10/29). Most
cryptococcal infections involved the brain (n = 27) and/or the blood
(n = 4) and/or the skin (n = 4) and/or the lung (n = 2) and/or soft tissue
(n = 1), or the transplanted kidney (n = 1). Due to the neurotropism of
the C. neoformans/C. gattii species complex, fever (100%, 29/29),
headache (96.6%, 28/29), meningeal irritation such as neck stiffness
(20.7%, 6/29), vomiting (10.3%, 3/29), and confusion (6.9%, 2/29) were
the most common clinical manifestations of cryptococcosis after
kidney transplantation. Of note, vision loss was frequently observed
(13.8%, 4/29) during the antifungal treatment period, even in some
cured cases. In addition, cerebrospinal ﬂuid (CSF) pressure was
described in 20 cases; in eight cases the CSF pressure was greater than
40 kPa. Details are shown in Table 2.
3.5. Diagnosis proﬁle
In this study, morphology based methods such as India ink
staining, culture, and the detection of cryptococcal antigen (Cr Ag)
were the main diagnostic approaches for the cryptococcal
infection. Among the 29 cases, 27 (93.1%) had positive results
for India ink staining and 23 (79.3%) had positive culture results.
Only 11 patients (37.9%) were diagnosed with a positive result for
Cr Ag in the CSF; 9 of these 11 patients also had a positive result forCr Ag in serum taken at the same time. Pulmonary cryptococcosis
was diagnosed using a combination of lung tissue biopsy and
medical imaging in the two cases. Although the clinical diagnostic
speciﬁcity of medical imaging features (e.g., computed tomogra-
phy (CT) and magnetic resonance imaging (MRI)) is relatively
limited, an MRI scan of case 8 showed brain hydrocephalus and a
CT scan of case 5 showed a cavity in the left lower lung that
improved after antifungal treatment. Details of these cases are
given in Table 2 and Figure 1.
3.6. Antifungal treatment
Detailed antifungal treatment information including the
induction and consolidation therapy was available for 12 cases
in this study. During the period of induction therapy in these 12
cases, liposomal AmB in combination with 5-FC was used in two
cases (one cured and one died); liposomal AmB in combination
with ITZ was used in one case (cured); liposomal AmB in
combination with 5-FC was used in two cases (one case cured
and one case died); liposomal AmB and VCZ in combination with 5-
FC was used in three cases (two case cured and one case died); FCZ
was used alone in three cases (three cases cured); FCZ in
combination with 5-FC was used in one case (cured); FCZ and
VCZ in combination with 5-FC was used in one case (died); VCZ in
combination with 5-FC was used in one case (cured); and
liposomal AmB was used alone in one case (cured). All 12 cases
were treated with FCZ (400 mg/day) during the period of induction
therapy. In addition, AmB, ITZ, and allicin were each used in four
cases during the period of induction therapy. Regarding consoli-
dation therapy, FCZ was used in all cases for which detailed data
were available in this study. According to the data from our survey,
the immunosuppressive strategy was slightly different among the
kidney transplant recipients in China. Steroids and calcineurin
inhibitors were mainly used in these patients. Details are given in
Table 3.
4. Discussion
Although several previous studies on cryptococcosis have
suggested that these infections most often occur in apparently
immunocompetent patients,16–18,27,42 separate case reports of
cryptococcosis occurring after kidney transplantation have been
reported continually since 1982 in China.28–40 According to a
review of cryptococcosis, approximately 0.76% of cryptococcosis
cases are estimated to be associated with kidney transplantation in
China.27 Moreover, it was estimated that 100 000 patients had
received a kidney transplant in China up to 2009.16 Hence,
cryptococcosis following kidney transplantation in mainland
Table 2
Clinical characteristics of cryptococcosis after kidney transplantation in mainland China, 1982–2013
Case Collection
date
Sex/ age Underlying
diseases
Geographical
distribution
Onset time
(years)
Pigeon
contact
Affected
site
Clinical
manifestations
CSF
pressure
(kPa)
India ink
stain
Culture CSF
Cr Ag
Serum
Cr Ag
CT scan Brain MRI Ref.
1 Nov 2003 M/43 Hepatitis C,
type 2 DM
Shanghai 13 No Brain Headache + fever 14.7 Neg Pos 1:1280 1:80 ND Hydrocephalus;
ventriculomegaly
This study
2 Dec 2005 M/ 43 No Shanghai 5.5 No Brain Headache + fever 53 Pos Pos 1:640 1:1280 ND Communicating
hydrocephalus
This study
3 Apr 2008 F/ 40 No Shanghai 3.1 No Brain Headache + fever 20 Neg Pos 1:320 1:320 ND ND This study
4 Oct 2008 M/ 42 No Shanghai 7 No Brain Headache + fever +
vomiting
53 Pos Pos 1:64 1:320 ND ND This study
5 Sep 2009 M/ 49 No Shanghai 5 No Brain + lung Headache + fever +
cough
53 Pos Pos 1:320 1:1280 Cavity in lung Hydrocephalus This study
6 Aug 2010 M/ 35 HTN Shanghai 3.1 No Brain Headache + fever +
vomiting
ND Pos Neg ND ND ND ND This study
7 Nov 2011 F/ 47 Hepatitis C Shanghai 18 No Brain Headache + fever 27 Pos Pos 1:80 1:320 ND Cerebral infarction This study
8 Apr 2012 M/ 36 No Shanghai 2 No Brain + lung Headache + fever 20 Pos Pos 1:160 1:1280 Cavity in lung Cerebral infarction This study
9 Jul 2012 F/ 45 No Shanghai 5 No Brain Headache + fever +
confusion
53 Pos Pos 1:640 1:1280 ND Cerebral ischemia This study
10 May 1982 M/ 29 ND Chuangchun 0.5 ND Brain Headache + fever ND Pos ND ND ND ND ND 29
11 Jul 1991 M/ 47 ND Lishui 1.5 Yes Brain Headache + fever +
cough + vision loss
3.91 Pos ND ND ND ND ND 30
12 Apr 1996 M/ 62 ND Beijing 2.5 ND Brain Headache + fever +
neck stiffness
3.63 Pos ND ND ND Hydrocephalus ND 31
13 Sep 1996 M/ 35 TB Beijing 3.5 ND Brain Headache + fever ND Pos Pos ND ND Hydrocephalus ND 32
14 Dec 1996 M/ 27 ND Chengdu 3.5 ND Brain Headache + fever +
neck stiffness
ND Pos ND ND ND ND ND 33
15 Dec 1996 F/ 41 ND Chengdu 3.5 ND Brain Headache + fever ND Pos Pos ND ND ND ND 33
16 Jan 1997 M/ 63 ND Beijing 2.5 ND Brain Headache + fever +
neck stiffness
39.2 Pos Pos ND ND Hydrocephalus Hydrocephalus 34
17 Feb 1998 F/ 50 ND Fuzhou 5 ND Brain Headache + fever +
neck stiffness
3.5 Pos Pos 1: 2560 ND ND ND 35
18 Feb 1998 M/ 24 ND Fuzhou 6 ND Brain Headache + fever 2.8 Pos Pos 1: 320 ND ND ND 35
19 Feb 1999 M/ 24 ND Guangzhou 2 ND Brain Headache + fever +
vision loss
ND Pos Pos ND ND ND ND 36
20 Oct 2004 F/ 34 ND Nanjing 6 ND Skin Fever ND Pos Pos ND ND ND ND 37
21 Jan 2005 M/ 49 ND Tangshan 4 ND Brain Headache + fever 33.3 Pos Pos ND ND ND ND 38
22 Jul 2008 F/ 35 ND Hefei 13 ND Brain Headache + fever +
vomiting
ND Pos Pos ND ND ND ND 39
23 Dec 2010 F/ 36 ND Fuzhou 0.03 ND Transplanted kidney Headache + fever +
confusion
ND Pos ND ND ND ND ND 40
24 Feb 2012 F/ 34 No Nanjing 6 ND Brain + blood + soft
tissues + skin
Headache + fever 54.6 Pos Pos ND ND ND ND 41
25 Feb 2012 M/ 35 ND Nanjing 5 ND Brain Headache + fever 53.3 Pos Pos ND ND ND ND 41
26 Feb 2012 F/ 53 Hepatitis C Nanjing 5 ND Brain Headache + fever +
neck stiffness
46 Pos Pos ND ND ND ND 41
27 Feb 2012 F/ 50 Type 2 DM Nanjing 3.1 ND Brain + blood + skin Headache + fever +
vision loss
31.3 Pos Pos ND 1:32 ND ND 41
28 Feb 2012 M/ 24 ND Nanjing 6 ND Brain + blood + skin Headache + fever +
vision loss + neck
stiffness
46.7 Pos Pos ND ND ND ND 41
29 Feb 2012 M/ 39 Hepatitis B Nanjing 10 Yes Brain + blood Headache + fever 34.7 Pos Pos 1:32 1:32 ND ND 41
CSF, cerebrospinal ﬂuid; Cr Ag, cryptococcal antigen; CT, computed tomography; MRI, magnetic resonance imaging; M, male; F, female; ND, no data; DM, diabetes mellitus; HTN, hypertension; TB, tuberculosis.
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Figure 1. CT scan of case 5 showing a spherical cavity in the dorsal segment of the left lower lung prior to pretreatment; this cavity was nearly absorbed after antifungal
treatment. MRI of case 8 showing brain hydrocephalus during the early stages.
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in this region remain unclear.
Although an accurate incidence of cryptococcosis after kidney
transplantation in China could not be calculated in this study, it
can be estimated at 0.58% (9/1550) from the internal data of
our hospital during the recent decade; this incidence is similar
to that reported from recent surveillance in mainland China
(0.76%) and the USA (0.2% to 5%).2,27 Regarding the clinical
outcome, 34.5% of cryptococcosis patients included in this study
died due to multiple organ failure, hypokalemia, and cerebral
hernia during the antifungal treatment period. This mortality
rate is in agreement with those of a previous report on mortality
rates in SOD recipients in which the rate for cryptococcosis was
found to range typically from 20% to 49%.20
Unlike the results of the recent cryptococcosis survey in
China,27 the most common underlying diseases in kidney
transplant recipients with cryptococcosis in our study were
hepatitis C (21.4%) and type 2 diabetes (14.3%); this is possibly
due to blood transfusion and the high prevalence of diabetes in
China. Moreover, no kidney transplant recipient with cryptococ-
cosis in this survey was positive for HIV, although approximately
7% of AIDS patients in China are affected by cryptococcosis.17
Remarkably, all 29 cases in this study were collected from
medical center cities. In our opinion, this is because of the
relatively high level of kidney transplantation and diagnosis ofcryptococcosis in these cities in China. In addition, a total of two
patients had come into contact with pigeon droppings before
cryptococcal infection in this study. Pigeon droppings may also be
a risk factor for cryptococcosis among kidney transplant recipients.
These ﬁndings highlight the need for further studies on the ecology
of this species complex and the resulting infection in kidney
transplant recipients in China.
Worldwide, approximately 50–75% of SOT recipients with
cryptococcosis have brain involvement.4,5,20,35 In this survey, the
brain was the organ most frequently associated with cryptococcosis
(93.1%), however infections of the lung, skin, and even the
transplanted kidney, as well as disseminated infection, also
occurred. Our survey also showed that among the kidney transplant
recipients, cryptococcal infection more frequently affected males
(male:female ratio 1.6:1); this is in agreement with the data
reported from a European survey (male:female ratio 2:1).44
Moreover, our data showed the age range 41–50 years (37.9%, 11/
29) to be the most heavily represented age group of these
immunosuppressed hosts. This ﬁnding is somewhat in contrast to
the data reported in a European survey, which found that the most
heavily represented age group was 31–40 years (53.8%).44
Previous reports have revealed genotype VNI isolates belonging
to C. neoformans var. grubii to be the most represented cryptococcal
isolates in China.16–18 Our ﬁndings are in agreement with those of
previous reports. However, a case of disseminated cryptococcosis
Table 3
Antifungal treatment of cryptococcal meningitis associated with kidney transplant recipients
Case Immunosuppressive
strategy
FK506/CsA
(ng/ml)
Antifungal treatment Outcome Ref.
Induction therapy Consolidation therapy
1 FK506 + MMF + Pred ND/ND (Liposomal AmB 2 mg/kg/day + 5-FC 100
mg/kg/day)  8 weeks; intrathecal
injection of AmB (cumulative dose, 0.5 g)
FCZ 400 mg/day  16 weeks Cured This study
2 FK506 + MMF + Pred ND/ND (Liposomal AmB 2 mg/kg/day + 5-FC 100
mg/kg/day)  8 weeks; intrathecal
injection of AmB (cumulative dose, 0.8 g)
FCZ 400 mg/day  2 weeks Died This study
3 FK506 + MMF + Pred 2.5/ND FCZ 400 mg/day  8 weeks FCZ 400 mg/day  12 weeks Cured This study
4 FK506 + Pred 5/ND (Liposomal AmB 2 mg/kg/day + ITZ 400
mg/kg/day)  8 weeks
FCZ 400 mg/day  12 weeks Cured This study
5 CsA + MMF + Pred ND/81.9 (Liposomal AmB 3 mg/kg/day + 5-FC 100
mg/kg/day + VCZ 4 mg/kg/day)  4 weeks
FCZ 400 mg/day  16 weeks Cured This study
6 FK506 + MMF ND/ND (Liposomal AmB 2 mg/kg/day + 5-FC 100
mg/kg/day + VCZ 4 mg/kg/day)  2 weeks
ND Died This study
7 CsA + MMF + Pred ND/162 (5-FC 100 mg/kg/day + VCZ 4 mg/kg/day)
 6 weeks
FCZ 400 mg/day  20 weeks Cured This study
8 FK506 + MMF + Medrol ND/3.2 (Liposomal AmB 3 mg/kg/day + 5-FC 100
mg/kg/day + VCZ 4 mg/kg/day)  8
weeks; intrathecal injection of AmB
(cumulative dose, 0.4 g)
FCZ 400 mg/day  20 weeks Cured This study
9 FK506 + Medrol 16.2/ND (FCZ 400 mg/day + 5-FC 100 mg/kg/day +
VCZ 4 mg/kg/day)  2 weeks
ND Died This study
10 ND ND/ND Allicin ND Died 29
11 Aza + Pred ND/ND (AmB + 5-FC)  6 weeks ND Died 30
12 Aza + Pred ND/ND (FCZ 400 mg/day + 5-FC 100 mg/kg/day)
 10 weeks
FCZ 400 mg/day  20 weeks Cured 31
13 CsA + Aza + Pred ND/ND (FCZ + 5-FC + allicin)  12 weeks ND Cured 32
14 CsA + Aza + Pred ND/ND FCZ 400 mg/day  8 weeks ND Cured 33
15 CsA + Aza + Pred ND/ND FCZ 400 mg/day  8 weeks FCZ 400 mg/day  16 weeks Cured 33
16 CsA + Aza + Pred ND/ND FCZ 400 mg/day  8 weeks FCZ 400 mg/day  12 weeks Cured 34
17 Aza ND/ND FCZ 200 mg/day  5 weeks ND Died 35
18 Aza ND/ND FCZ 200 mg/day  8 weeks ND Cured 35
19 Pred ND/ND (FCZ + 5-FC + allicin)  8 weeks ND Cured 36
20 Aza ND/ND FCZ 200 mg/day  8 weeks ND Cured 37
21 FK506 + MMF + Pred ND/ND AmB 25 mg/day  8 weeks ND Cured 38
22 CsA + Pred ND/ND Liposomal AmB 30 mg/day  12 weeks FCZ 200 mg/day  12 weeks Cured 39
23 FK506 + MMF + Pred 18.4/ND ND ND Died 40
24 CsA + Aza + Pred ND/34.6 FCZ ND Cured 41
25 FK506 + MMF + Pred ND/76 FCZ ND Died 41
26 FK506 + MMF + Pred 10.8/ND FCZ ND Died 41
27 FK506 + MMF + Pred 12.0/ND ITZ ND Died 41
28 FK506 + MMF + Pred 3.6/ND FCZ ND Cured 41
29 FK506 + MMF + Pred 4.1/ND FCZ+VCZ ND Cured 41
FK506, tacrolimus; CsA, cyclosporin A; MMF, mycophenolate mofetil; Pred, prednisone; ND, no data; AmB, amphotericin B; 5-FC, 5-ﬂuorocytosine; FCZ, ﬂuconazole; ITZ,
itraconazole; VCZ, voriconazole; Medrol, methyl prednisone; Aza, azathioprine.
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in Korea has been reported.43
Although liposomal amphotericin B with ﬂucytosine is listed as
the ﬁrst choice treatment for cryptococcosis in kidney transplant
patients in clinical practice guidelines,45 VCZ may also be a
potentially valuable treatment for cryptococcosis following kidney
transplantation.27,46
Similar to the ﬁndings of the recent overview of cryptococcosis
in China,27 fever, headache, meningeal irritation, vomiting, and
confusion were also the most common clinical manifestations of
cryptococcal infection after kidney transplantation in China. In our
opinion, physicians should be particularly alert to slight to
moderate headache with fever in kidney transplant recipients.
Cryptococcosis in kidney transplant recipients is typically a
late-occurring infection.1 It has been hypothesized that crypto-
coccosis may result from either primary infection or reactivation
of a latent infection.50 Cryptococcal infection usually occurs >1
year after kidney transplantation and is generally considered to
represent reactivation of a latent infection.47,50 In a recent survey
of cryptococcosis among SOT patients, the median time to onset
was 575 days post transplant, and 75% of cases occurred at <3years post transplant.4 In this study, 93.1% (27/29) of the
infections occurred >1 year after the transplant, and 79.3%
(23/29) of the cases occurred >3 years after the transplant. These
results are somewhat in contrast to the data reported from other
countries. Of note, case 23 in the present study exhibited an
early onset (<2 weeks), which prompts a suspicion of donor
transmission.
The plasma concentration of immunosuppressive drugs such as
FK506 is also regarded as a risk factor for cryptococcal infection
among kidney transplant recipients.1 However, only 27.6% (8/29)
of recipients were found to have been tested for this in the present
survey, which is possibly due to some Chinese clinical physicians
still not being aware of the importance of the plasma concentration
of immunosuppressive drugs in kidney transplant recipients.
Further studies on cryptococcosis among kidney transplant
recipients are needed.
C. gattii more frequently causes high CSF pressure and
neurological abnormalities such as vision loss,9 but 40% of the
patients presented a high CSF pressure (>39.2 kPa) and 13.8% of
the patients presented vision loss in this study, in spite of all
recipients being infected by C. neoformans var. grubii.
Y.- Yang et al. / International Journal of Infectious Diseases 26 (2014) 154–161160Currently, the diagnosis of cryptococcosis relying only on
clinical manifestations, particularly in the early stages of this
infection, is a challenge to clinical physicians. Morphology based
methods such as India ink staining, culture, and the detection of
cryptococcal antigen (Cr Ag) are at present the main diagnostic
approaches for cryptococcosis. Unlike previous studies,48 no
difference in Cr Ag in serum could be found between central
nervous system (CNS) and pulmonary infections in this study,
which is possibly due to the limited number of cases. However, our
ﬁndings still suggest that fully utilizing the existing diagnostic
techniques for cryptococcosis in cases of a suspected renal
transplant-associated cryptococcal infection is essential.20,47
Radiographic imaging is also an important diagnostic approach
in cryptococcosis patients following kidney transplantation, with
particular implications for clinical outcome and treatment.1
Compared to populations with normal immune systems, radio-
graphic abnormalities are more likely to occur in renal transplant
recipients.49 Although radiographic examinations are frequently
non-speciﬁc, radiographic examinations such as CT and MRI are
effective in the diagnosis of cryptococcosis, particularly in
determining the site and extent of infection, and allow for
treatment in the renal transplant recipients group. A good example
from our survey is that of case 5, in whom a CT scan revealed a
spherical cavity in the dorsal segment of the left lower lung prior to
pretreatment; this cavity was nearly absorbed by day 82 of
antifungal treatment.
According to recent guidelines, the antifungal treatment of
cryptococcosis among kidney transplant recipients should
include liposomal AmB plus 5-FC as the ﬁrst choice for induction
therapy, and FCZ is the ﬁrst recommendation for consolidation
therapy.45 Although consolidation treatment of Chinese kidney
transplant recipients is in agreement with the recommendations
of those guidelines, apparent differences exist between our
ﬁndings and the guidelines with regard to induction therapy. In
addition to liposomal AmB and 5-FC, another four types of
antifungal agent were used during the induction therapy period
in 27 kidney transplant recipients in China, including FCZ, VCZ,
ITZ, and allicin, and 18 recipients were cured. In addition, three
patients had intrathecal injection of AmB in our hospital for
better therapeutic effect and control of intracranial hyperten-
sion. In fact, intrathecal injection of AmB is considered
an effective treatment method for CNS cryptococcosis in
China.27 Although there were differences in induction therapy
between the cases reported in the present study and those
recommended in the guidelines, the mortality rate found in
China (34.5%) is similar to the data from other countries (20% to
49%).1,20 Further clinical studies on optimizing antifungal
treatment for kidney transplant recipients also need to be
performed in the future.
In conclusion, cryptococcosis is a serious infection among
kidney transplant recipients in China that is primarily caused by C.
neoformans var. grubii VNI strains; patients aged 41–50 years are
most commonly affected and they present non-speciﬁc clinical
manifestations and have a relatively long time to onset after
kidney transplantation. Furthermore, all of the cryptococcosis
cases included in the present study were from areas of China
where medical practice is well developed, which implies that
many cases in rural or poor areas of China may be misdiagnosed or
missed. Owing to the limited number of cases, and some of them
without complete clinical data, we could not deﬁnitively
determine the full proﬁle of the association of cryptococcosis
with kidney transplantation in this study. Hence, multicenter,
prospective, and multidisciplinary clinical studies and further
education on cryptococcosis among kidney transplant recipients
in countries that perform many such SOTs, such as China, are
needed.Acknowledgements
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